Jemperli
Jul 27, 2026
PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?
Summary The PD-1 inhibitors market is led by Merck’s KEYTRUDA and Bristol Myers Squibb’s OPDIVO, which together still dominate global revenue and remain the standard-bearers in the category. Challenger PD-1 drugs such as Sanofi/Regeneron’s LIBTAYO, GSK’s JEMPERLI, and Incyte’s ZYNYZ have carved out positions...
Read More...
Aug 01, 2023
FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa
FDA Expands GSK’s Jemperli Approval for Endometrial Cancer GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with mismatch repair deficient...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
